News and Trends 27 May 2022 Up to 500 new jobs as Lilly invests $2.1B in new manufacturing sites Eli Lilly and Company is boosting its manufacturing footprint by investing $2.1 billion in two new U.S. sites. The new facilities are located at Indiana’s LEAP Lebanon Innovation and Research District in Boone County. David A. Ricks, Lilly’s chair and CEO, said: “These new sites will add capacity in support of our growing pipeline of […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 HotSpot looks to boost cancer therapy pipeline with Excelra partnership U.S. biotech company HotSpot Therapeutics, Inc. is looking to increase its drug development and discovery efforts by partnering with Indian data and digital insights company Excelra. HotSpot discovers and develops small molecule allosteric therapies for the treatment of cancer and autoimmune diseases. What are allosteric therapies? In the journal ACS Medicinal Chemistry Letters, Ahmed F. […] May 27, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Companies partner on early lung cancer detection blood test U.S. company CorePath Laboratories is partnering with U.K. diagnostics firm Cizzle Biotechnology on an early-stage lung cancer test for the U.S. Lung cancer is the leading cause of cancer deaths in the U.S., making up almost 25% of all cancer deaths. Each year, more people die of lung cancer than of colon, breast, and prostate […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Blue Lake Biotechnology RSV vaccine gets FDA fast track U.S. company Blue Lake Biotechnology, Inc. has received U.S. Food and Drug Administration (FDA) Fast Track designation for its respiratory syncytial virus (RSV) intranasal vaccine. The biopharma company, a subsidiary of CyanVac LLC, develops vaccines using a parainfluenza virus 5 (PIV5)-based vector. The FDA Fast Track designation applies to BLB-201, a vaccine for the prevention […] May 27, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 27 May 2022 Animal-free milk company Imagindairy reaches $28M in funding Israeli foodtech startup Imagindairy, Ltd., developer of animal-free dairy milk proteins, has secured an additional $15M in its extended seed-round to bring the total investment so far to $28M. The alt-protein company creates animal-free milk proteins from microorganisms through precision-fermentation technology, which allows the production of a wide range of dairy analogs, from raw milk […] May 27, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2022 Duke Street Bio enters stage with next-generation cancer therapies The UK startup Duke Street Bio has exited stealth mode with funding to develop PARP enzyme inhibitors that treat cancer by blocking the repair of DNA in tumor cells. London-based Duke Street Bio said Tuesday that it has a portfolio of PARP1 and PARP7 enzyme inhibitors and has raised enough cash to fund its pipeline […] May 25, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
Inside Labiotech 25 May 2022 Labiotech goes global The past few months have been very exciting for our team. Following our recent acquisition by Inova, we’ve been working hard on defining the future of Labiotech. From our humble beginnings in France to our expansion into the European market, we’ve always been keen to explore new horizons for the benefit of our readers. Once […] May 25, 2022 - 3 minutesmins - By Joachim Eeckhout Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2022 Vaccines mobilized to control monkeypox outbreak An unusual outbreak of monkeypox is causing concern worldwide in the shadow of the destructive Covid-19 pandemic. Both old and emerging vaccine technology could aid the fight against the outbreak. In the wake of the world-changing Covid-19 pandemic, the World Health Organization (WHO) is voicing alarm over another unusual outbreak, this time of the viral […] May 24, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
In Depth 23 May 2022 The coming of age of European synthetic biology Within a few years, synthetic biology has evolved from being a new player in the molecular biology and biotech arena to being a front-row contender with multiple industrial advances and large amounts of investor money. There have been a number of definitions of synthetic biology, also known as synbio. Generally, it involves redesigning genetic systems […] May 23, 2022 - 8 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2022 Zealand Pharma’s drug for rare metabolic disease smashes phase III After a year of slumping stock prices, Zealand Pharma is striking back, as its peptide drug improved blood sugar control in infants with the rare disease congenital hyperinsulinemia in a phase III trial. In late 2020, the Danish firm Zealand Pharma A/S hit a big obstacle when its peptide drug dasiglucagon failed to treat the […] May 20, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 Evotec, Sernova in partnership to develop beta cell diabetes therapy Evotec and Sernova are set to join forces to advance a beta cell replacement therapy to treat insulin-dependent diabetes. As part of the deal, Evotec will make a €20M equity investment in Sernova. Germany-based Evotec and Canada’s Sernova have agreed on a partnership to develop and commercialize an implantable diabetes therapy based on beta cell […] May 19, 2022 - 3 minutesmins - By Susannah Rodgers Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2022 F2G enlists Shionogi to bring antifungal treatment to Europe and Asia The UK company F2G Ltd. has announced a strategic collaboration with Japanese pharmaceutical company Shionogi & Co. Ltd. to develop and commercialize olorofim, an antifungal treatment for invasive fungal infections, in Europe and Asia. The deal centers on olorofim, F2G’s oral antifungal therapy for the treatment of invasive aspergillosis, an infection that can be deadly […] May 19, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email